Buttigliero C - Search Results

1

TEAM Study: Upfront Docetaxel Treatment in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World, Multicenter, Retrospective Analysis.

Pisano C, Turco F, Arnaudo E, Fea E, Vanella P, Ruatta F, Filippi R, Brusa F, Prati V, Vana F, Mennitto A, Cattrini C, Vignani F, Dionisio R, Icardi M, Guglielmini P, Buosi R, Stevani I, Vormola R, Numico G, Depetris I, Comandone A, Gennari A, Airoldi M, Rossi M, Vellani G, Ortega C, Tucci M, Maio MD, Buttigliero C. Pisano C, et al. Among authors: buttigliero c. Clin Genitourin Cancer. 2024 Apr;22(2):56-67.e16. doi: 10.1016/j.clgc.2023.08.006. Epub 2023 Sep 7. Clin Genitourin Cancer. 2024. PMID: 37798164

2

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Powles T, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Gurney H, Chang YH, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Burgents JE, Xu L, Imai K, Quinn DI, Choueiri TK; KEYNOTE-564 Investigators. Powles T, et al. Lancet Oncol. 2022 Sep;23(9):1133-1144. doi: 10.1016/S1470-2045(22)00487-9. Lancet Oncol. 2022. PMID: 36055304 Free article. Clinical Trial.

3

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

Berruti A, Buttigliero C, Dogliotti L. Berruti A, et al. Among authors: buttigliero c. N Engl J Med. 2009 May 28;360(22):2368; author reply 2369-70. N Engl J Med. 2009. PMID: 19484817 No abstract available.

4

Pitfalls in the diagnosis of adrenocortical tumors: a lesson from 300 consultation cases.

Duregon E, Volante M, Bollito E, Goia M, Buttigliero C, Zaggia B, Berruti A, Scagliotti GV, Papotti M. Duregon E, et al. Among authors: buttigliero c. Hum Pathol. 2015 Dec;46(12):1799-807. doi: 10.1016/j.humpath.2015.08.012. Epub 2015 Sep 11. Hum Pathol. 2015. PMID: 26472162

5

Effects of serum testosterone levels after 6 months of androgen deprivation therapy on the outcome of patients with prostate cancer.

Bertaglia V, Tucci M, Fiori C, Aroasio E, Poggio M, Buttigliero C, Grande S, Saini A, Porpiglia F, Berruti A. Bertaglia V, et al. Among authors: buttigliero c. Clin Genitourin Cancer. 2013 Sep;11(3):325-330.e1. doi: 10.1016/j.clgc.2013.01.002. Epub 2013 Mar 23. Clin Genitourin Cancer. 2013. PMID: 23531429

6

Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study.

Caffo O, De Giorgi U, Fratino L, Alesini D, Zagonel V, Facchini G, Gasparro D, Ortega C, Tucci M, Verderame F, Campadelli E, Lo Re G, Procopio G, Sabbatini R, Donini M, Morelli F, Sartori D, Zucali P, Carrozza F, D'Angelo A, Vicario G, Massari F, Santini D, Sava T, Messina C, Fornarini G, La Torre L, Ricotta R, Aieta M, Mucciarini C, Zustovich F, Macrini S, Burgio SL, Santarossa S, D'Aniello C, Basso U, Tarasconi S, Cortesi E, Buttigliero C, Ruatta F, Veccia A, Conteduca V, Maines F, Galligioni E. Caffo O, et al. Among authors: buttigliero c. Eur Urol. 2015 Jul;68(1):147-53. doi: 10.1016/j.eururo.2014.10.014. Epub 2014 Oct 25. Eur Urol. 2015. PMID: 25457020

7

The fat body mass increase after adjuvant androgen deprivation therapy is predictive of prostate cancer outcome.

Buttigliero C, Vana F, Bertaglia V, Vignani F, Fiori C, Osella G, Porpiglia F, Tucci M, Scagliotti GV, Berruti A. Buttigliero C, et al. Endocrine. 2015 Sep;50(1):223-30. doi: 10.1007/s12020-015-0525-x. Epub 2015 Jan 15. Endocrine. 2015. PMID: 25588772 Free article.

8

Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment.

Iuliani M, Pantano F, Buttigliero C, Fioramonti M, Bertaglia V, Vincenzi B, Zoccoli A, Ribelli G, Tucci M, Vignani F, Berruti A, Scagliotti GV, Tonini G, Santini D. Iuliani M, et al. Among authors: buttigliero c. Oncotarget. 2015 May 20;6(14):12520-8. doi: 10.18632/oncotarget.3724. Oncotarget. 2015. PMID: 25904051 Free PMC article.

9

Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer.

Buttigliero C, Tucci M, Bertaglia V, Vignani F, Bironzo P, Di Maio M, Scagliotti GV. Buttigliero C, et al. Cancer Treat Rev. 2015 Dec;41(10):884-92. doi: 10.1016/j.ctrv.2015.08.002. Epub 2015 Aug 31. Cancer Treat Rev. 2015. PMID: 26342718 Free article. Review.

10

Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.

Tucci M, Bertaglia V, Vignani F, Buttigliero C, Fiori C, Porpiglia F, Scagliotti GV, Di Maio M. Tucci M, et al. Among authors: buttigliero c. Eur Urol. 2016 Apr;69(4):563-573. doi: 10.1016/j.eururo.2015.09.013. Epub 2015 Sep 28. Eur Urol. 2016. PMID: 26422676 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

91 results

Search Page